In an international study evaluating the molecular and clinical architecture of systemic anaplastic large cell lymphoma, researchers discovered that distinct genomic profiles define anaplastic lymphoma kinase-positive and kinase-negative diseases, directly impacting patient survival. Across a centrally reviewed cohort of one hundred and forty-nine biopsy samples, tumors lacking anaplastic lymphoma kinase rearrangements demonstrated significantly worse overall survival and progression-free survival compared to kinase-positive counterparts. Within the kinase-negative subgroup, tumors harboring somatic mutations in TP53 exhibited the poorest clinical outcomes, accompanied by the highest mutational load and the most extensive copy number alteration burden across the entire study population. Furthermore, the investigative team identified a prognostic three-gene composite signature comprising TP53, KMT2D, and TET2 that robustly stratified overall survival risk across diagnostic subtypes. These findings define divergent biological landscapes between the two major systemic lymphoma variants, demonstrating that secondary genomic alterations account for substantial heterogeneity in disease progression and therapeutic response.
Systemic anaplastic large cell lymphoma represents an uncommon yet aggressive mature T-cell lymphoma, morphologically hallmarked by large pleomorphic lymphocytes with irregular kidney-shaped nuclei and uniform CD30 expression. Under international diagnostic classifications, systemic cases are divided into distinct categories according to anaplastic lymphoma kinase protein expression, which reflects underlying chromosomal rearrangements involving the receptor tyrosine kinase locus. While frontline management has conventionally relied on multi-agent anthracycline-based chemotherapy regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone, recent advances have incorporated the CD30-directed antibody-drug conjugate brentuximab vedotin, alongside kinase inhibitors such as crizotinib for selected relapsed or refractory cases. Despite these treatments, clinical trajectories remain heterogeneous, particularly within kinase-negative disease where subgroupings based on recurrent rearrangements involving DUSP22 and TP63 fail to capture the full spectrum of patient risk. Consequently, comprehensive molecular characterization is essential to uncover the genetic determinants governing therapeutic sensitivity and clinical outcomes.
To investigate the genomic mechanisms governing clinical disparity, investigators analyzed formalin-fixed, paraffin-embedded tumor specimens from one hundred and forty-nine patients accrued through the Atlas of Blood Cancer Genomes project, an international collaboration spanning twenty-five clinical centers. All biopsy specimens underwent centralized histological review by expert hematopathologists prior to molecular profiling. The cohort divided almost evenly between subtypes, comprising seventy-five kinase-positive cases and seventy-four kinase-negative cases. Baseline clinical characteristics showed a median patient age at diagnosis of 55.6 years, ranging from 3.6 to 91.9 years, with an overall male predominance accounting for sixty-five percent of evaluable cases. Patient age diverged markedly by diagnostic subgroup: kinase-positive patients presented at a significantly younger median age of 39.9 years compared with 61.8 years in kinase-negative patients, with eighteen percent versus fifty-five percent aged over sixty years. Frontline treatment details confirmed that ninety-one percent of patients received curative-intent regimens, predominantly standard cyclophosphamide, doxorubicin, vincristine, and prednisone, with treatment intent showing no significant difference between diagnostic categories.
The molecular profiling framework integrated parallel high-throughput sequencing assays to interrogate single-nucleotide variants, structural rearrangements, copy number alterations, and whole-transcriptome expression profiles. Genomic DNA extracted from clinical samples was evaluated using whole-exome sequencing, reaching an average sequencing depth of 34-fold coverage across one hundred and twenty passing specimens, alongside an additional targeted gene panel covering all known blood cancer driver genes at 166-fold coverage across one hundred and twenty-three passing specimens. Raw paired-end sequencing reads were processed through automated trimming to eliminate adapter contamination and low-quality bases, followed by alignment against the human reference genome GRCh38. Duplicate reads generated during polymerase chain reaction amplification were flagged and excluded using dedicated informatics pipelines. Driver alterations were identified using a consensus variant-calling approach that captured the union of mutations detected across Strelka2, DeepVariant, and Sentieon Haplotyper pipelines, filtering out synonymous variations and common germline polymorphisms exceeding one percent frequency before manual verification on the Integrative Genomics Viewer.
Transcriptomic profiling was accomplished using whole-transcriptome ribonucleic acid sequencing across one hundred and twenty-three successfully processed patient samples. Following adapter trimming and quality filtering, sequencing reads were aligned against the human reference genome utilizing the STAR aligner, with transcript abundance quantified using Salmon and tximport libraries before undergoing normalization through DESeq2. Copy number alterations were characterized across seventy-six exome-sequenced samples meeting strict quality metrics, utilizing CNVkit and GISTIC algorithms across a panel of one hundred and seventy-four cancer-associated genes. Structural chromosomal fusions were identified through the Arriba algorithm, requiring annotated database matches or high confidence metrics alongside split-read and mate-pair support thresholds to eliminate false-positive technical artifacts, with independent validation performed using STAR-Fusion. Furthermore, global genomic ancestry was inferred from linkage-disequilibrium-pruned single-nucleotide polymorphisms evaluated with ADMIXTURE across reference populations from the HapMap3 project, establishing standardized European, African, and Asian ancestry proportions for comparative clinical analyses.
Survival analyses confirmed that anaplastic lymphoma kinase translocation status strongly dictates patient outcomes, while also highlighting the confounding influence of baseline patient age and treatment selection. Univariate log-rank comparisons revealed significantly inferior overall survival and progression-free survival among kinase-negative patients, with univariate Cox proportional hazards regression demonstrating a hazard ratio of 2.14 for overall mortality and 3.16 for disease progression. However, because kinase-negative patients were substantially older, joint statistical modeling showed that adjusting for patient age alone attenuated the statistical significance of kinase status regarding overall survival. Crucially, when multivariable models incorporated both curative-intent frontline therapy and patient age, kinase-negative status retained independent adverse prognostic significance, conferring an adjusted hazard ratio of 2.50 for overall survival and 3.79 for progression-free survival. In this fully adjusted model, curative-intent therapy provided strong protection, reducing mortality hazards to 0.14, whereas older age remained independently adverse, demonstrating that apparent survival attenuations reflect treatment disparities rather than biological equivalence.
Evaluation of patient demographics revealed notable outcome disparities across self-reported racial groups and genetically determined ancestral backgrounds. Among individuals with recorded racial information, progression-free and overall survival differed significantly: White patients experienced the most favorable survival trajectories, followed by Asian patients, while Black patients exhibited the shortest survival durations. Genomic ancestry analysis corroborated these patterns, establishing that seventy-one point eight percent of the cohort possessed at least fifty percent European ancestry, fifteen percent had Asian ancestry, and fourteen percent had African ancestry. Univariate survival models demonstrated that individuals with predominantly African genomic ancestry experienced significantly worse progression-free and overall survival compared with other groups. However, multivariable sequential modeling revealed that this survival disparity was progressively attenuated after accounting for kinase status, treatment intent, and age, ultimately losing independent statistical significance. Because diagnostic subtypes, curative therapy rates, and baseline age were balanced across ancestral cohorts, researchers emphasized that these findings reflect unmeasured clinical factors rather than independent biological differences.
High-throughput mutation profiling identified distinct mutational burdens and signaling pathways operating across the two lymphoma entities. Tumors lacking kinase rearrangements exhibited a significantly higher overall burden of single-nucleotide variants and small insertions or deletions compared to kinase-positive tumors. Functional pathway clustering demonstrated that epigenetic modifiers constituted the largest altered functional group across all cases, comprising thirty-two percent of all observed mutational events, followed by DNA damage repair, Janus kinase and signal transducer pathways, and Notch signaling cascades. At the individual gene level, kinase-negative tumors were significantly enriched for mutations affecting TP53, STAT3, and KMT2D, along with recurrent alterations in JAK1, RAD50, and TET2 that each affected at least ten percent of patients. Conversely, kinase-positive lymphomas displayed frequent mutations in NOTCH1, NOTCH2, and BCL10. Notably, BCL10 mutations occurred almost exclusively in kinase-positive tumors, consisting entirely of small frameshift insertions and deletions, indicating divergent selective pressures on canonical signaling pathways between the two primary lymphoma subtypes.
The mutational status of TP53 emerged as the paramount molecular determinant of poor survival, particularly when cooperating with recurrent epigenetic disruptions. Patients with kinase-negative lymphomas carrying TP53 mutations experienced significantly shorter progression-free and overall survival than those with kinase-negative wild-type TP53 or kinase-positive disease. These TP53-mutant kinase-negative tumors displayed marked chromosomal instability, harboring both the highest total mutation counts and the greatest number of copy number alterations across the entire cohort. Mutational mapping revealed that TP53 alterations clustered predominantly within the core DNA-binding domain, featuring recurrent amino acid substitutions at codon R273. When investigators examined cooperation between TP53 and the frequently mutated epigenetic regulators KMT2D and TET2, patients harboring alterations in any of these three genes exhibited drastically reduced overall survival compared to wild-type cases. Sensitivity analyses demonstrated that this combined three-gene signature remained an independent predictor of overall mortality, with KMT2D or TET2 mutations independently predicting shorter survival even within the subset of patients with wild-type TP53.
Gene expression profiling and structural fusion analyses further elucidated the molecular divergence between the two diseases. Transcriptomic comparisons identified ninety-four differentially expressed genes, with kinase-negative tumors exhibiting prominent upregulation of immune and cellular stress programs, including non-canonical nuclear factor kappa B and interferon gamma pathways. Conversely, kinase-positive tumors showed heightened expression of transforming growth factor signaling alongside diagnostic fusion transcripts, most commonly involving NPM1 and ATIC partner genes. Within kinase-negative cases, mutually exclusive rearrangements involving TP63 and DUSP22 were confirmed, with TP63 fusions associating with significantly worse overall survival. Although limited by cohort size and retrospective treatment heterogeneity, these comprehensive clinico-genomic findings clarify that secondary mutational burden, defective DNA damage repair, and constitutive signaling govern the aggressive course of kinase-negative lymphoma. Consequently, these findings provide a mechanistic framework for future clinical trials to evaluate biology-directed therapeutic interventions, including targeted kinase inhibition and synthetic lethality strategies exploiting DNA repair deficiencies in biomarker-stratified patients.
Subject of Research: Genomic landscapes and clinical outcomes in systemic anaplastic large cell lymphoma
Article Title: Distinct genomic landscapes of ALK-positive and ALK-negative systemic anaplastic large cell lymphomas: clinical impacts and translational significance
Article References: Au-Yeung, R. K. H., Owusu, D., Russell, V., Kwong, Y.-L., Li, J., Lee, C., Gill, H., Ip, A., Choi, W., Koff, J. L., Jaye, D., Pedersen, M. Ø., Gang, A. O., Love, C., Shingleton, J. R., Biral, L. P. A., Thacker, E., Thakkar, D., Parker, C., … Tse, E. (2026). Distinct genomic landscapes of ALK-positive and ALK-negative systemic anaplastic large cell lymphomas: clinical impacts and translational significance. Biomarker Research, 14(1), Article 166. https://doi.org/10.1186/s40364-026-01039-2
Image Credits: AI Generated
DOI: 10.1186/s40364-026-01039-2
Keywords: anaplastic large cell lymphoma, systemic ALCL, ALK-positive ALCL, ALK-negative ALCL, TP53 mutation, KMT2D, TET2, JAK1, STAT3, whole exome sequencing, copy number variation, overall survival, progression-free survival, BCL10, NOTCH1, DUSP22, TP63, epigenetic regulators
